A Phase 2 interventional study of Collagenase Clostridium Histolyticum and Placebo in Edematous Fibrosclerotic Panniculopathy (EFP), sponsored by Endo Pharmaceuticals. Completed at 10 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.
Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 2, and was the 2nd registered.
71 studies on the registry are indexed under Cellulite; 3 are open to participants now.
Browse Cellulite studies →None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 34 across 65 interventional studies indexed under Cellulite.
Median enrollment 150 across the 15 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 2 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
18 studies in Cellulite by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 18 finished, 14 (78%) have results posted.
Among the 18 studies in Cellulite by Keenova Therapeutics plc, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 8 in phase 2, and was the 2nd registered.
Keenova Therapeutics plc’s Cellulite studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Microbial Collagenase in Cellulite, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 18 in Cellulite:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.
The Phase 2a study is a randomized, double-blind multiple-dose study that is expected to enroll approximately 144 women between the ages of 18 and 45 in the United States. Treatment effectiveness will be evaluated by investigator and patient assessments, as well as 3-D photographic imaging techniques. Once the safety and local tolerability profile from the first stage has been found to be acceptable subjects will be enrolled in stage 2. After an interim safety and local tolerability review was completed of all subjects in stage 1, it was determined that enrollment in stage 2 is acceptable and has been initiated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has used any of the following for the treatment of EFP on the legs or buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:
Has received any collagenase treatments within 30 days before treatment.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AA4500 (Collagenase Clostridium Histolyticum) Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
Biological: Collagenase Clostridium Histolyticum
AA4500 (Collagenase Clostridium Histolyticum) Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
Biological: Collagenase Clostridium Histolyticum
AA4500 (Collagenase Clostridium Histolyticum) Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
Biological: Collagenase Clostridium Histolyticum
Placebo Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
Biological: Placebo
injectible intervention
Also known as: AA4500, Xiaflex, Xiapex
Investigator Global Assessment of Aesthetic Improvement
Investigators assessment of aesthetic improvement (I-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).
Time frame: Baseline, Day 73
Investigator Cellulite Severity Score (CSS) Total Score- Change From Baseline
The CSS is a photonumeric scale that was used to evaluate 5 morphologic features of cellulite; (A) number of evident depressions, (B) depth of depressions, (C) morphological appearance of skin surface alterations, (D) laxity, flaccidity or sagging of skin, and (E) current classification scale based on medical literature including Nuernberger and Mueller. The severity of each feature is rated on a scale from 0 (none) to 3 (most severe). The CSS total score is the sum of the 5 cellulite features (range: 0 to 15, with higher scores corresponding to more severe cellulite). Change is Day 73 study visit rating minus baseline rating; negative values indicate improvement in cellulite.
Time frame: Baseline, Day 73
Subject Cellulite Severity Item (CSI)-Change From Baseline
CSI scores ranged from 0 (no cellulite present), 1 (very mild), 2 (mild), 3 (moderate), 4 (severe) to 5 (very severe). Change is Day 73 study visit rating minus baseline rating; negative values indicate a lessening in cellulite severity.
Time frame: Baseline, Day 73
Subject Global Bother Assessment (SGBA)- Change From Baseline
Subjects rated their cellulite on a scale from 0 (not at all bothered) to 4 (extremely bothered). Change from baseline is Day 73 study visit value minus baseline value; negative change reflects an improvement in the amount the subject was bothered by cellulite; positive change reflects a worsening in the amount the subject is bothered by cellulite.
Time frame: Baseline, Day 73
Subject-reported Cellulite Impact Scale (SR-CIS)-Change From Baseline
Subjects were asked to answer 6 exploratory questions regarding the appearance of their cellulite on a scale of 0 to 10 with 0 representing "not at all" and 10 representing "extremely." A SR-CIS total score was derived from these 6 questions with values varying from 0 (No negative impact) to 60 (Extreme negative impact). Change from baseline is Day 73 value minus baseline value; negative change reflects an improvement.
Time frame: Baseline, Day 73
Subject Satisfaction With Treatment Assessment (SCTA)
Subjects rated their treatment satisfaction at the Day 73 visit on a 5-point scale ranging from -2 (very dissatisfied) to +2 (very satisfied)
Time frame: Day 73
Subject Global Assessment Cellulite (SGA-C)
Subjects assessed their cellulite based on a 5-point scale from -1 (slightly worse), 0 (same), 1 (slightly improved), 2 (moderately improved), to 3 (much improved) on Day 73
Time frame: Day 73
Subject Global Assessment of Aesthetic Improvement (C-GAIS)
Subjects's assessment of aesthetic improvement (C-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).
Time frame: Day 73
| Milestone | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Started | 43 | 43 | 40 | 24 |
| Completed | 41 | 43 | 38 | 24 |
| Not completed | 2 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 2 | 0 |
Investigators assessment of aesthetic improvement (I-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Investigator Global Assessment of Aesthetic Improvement | 0.7 ± 0.82 | 0.9 ± 0.93 | 1.1 ± 0.91 | 0.5 ± 0.72 |
The CSS is a photonumeric scale that was used to evaluate 5 morphologic features of cellulite; (A) number of evident depressions, (B) depth of depressions, (C) morphological appearance of skin surface alterations, (D) laxity, flaccidity or sagging of skin, and (E) current classification scale based on medical literature including Nuernberger and Mueller. The severity of each feature is rated on a scale from 0 (none) to 3 (most severe). The CSS total score is the sum of the 5 cellulite features (range: 0 to 15, with higher scores corresponding to more severe cellulite). Change is Day 73 study visit rating minus baseline rating; negative values indicate improvement in cellulite.
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Investigator Cellulite Severity Score (CSS) Total Score- Change From Baseline | -1.1 ± 1.74 | -1.3 ± 1.70 | -1.9 ± 2.37 | -0.7 ± 1.52 |
CSI scores ranged from 0 (no cellulite present), 1 (very mild), 2 (mild), 3 (moderate), 4 (severe) to 5 (very severe). Change is Day 73 study visit rating minus baseline rating; negative values indicate a lessening in cellulite severity.
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Subject Cellulite Severity Item (CSI)-Change From Baseline | -0.7 ± 1.22 | -1.1 ± 1.07 | -1.3 ± 1.34 | -0.8 ± 1.35 |
Subjects rated their cellulite on a scale from 0 (not at all bothered) to 4 (extremely bothered). Change from baseline is Day 73 study visit value minus baseline value; negative change reflects an improvement in the amount the subject was bothered by cellulite; positive change reflects a worsening in the amount the subject is bothered by cellulite.
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Subject Global Bother Assessment (SGBA)- Change From Baseline | -0.9 ± 1.33 | -1.0 ± 1.23 | -1.0 ± 1.12 | -1.0 ± 1.33 |
Subjects were asked to answer 6 exploratory questions regarding the appearance of their cellulite on a scale of 0 to 10 with 0 representing "not at all" and 10 representing "extremely." A SR-CIS total score was derived from these 6 questions with values varying from 0 (No negative impact) to 60 (Extreme negative impact). Change from baseline is Day 73 value minus baseline value; negative change reflects an improvement.
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Subject-reported Cellulite Impact Scale (SR-CIS)-Change From Baseline | -15.0 ± 18.9 | -18.0 ± 15.70 | -17.7 ± 14.61 | -11.9 ± 13.97 |
Subjects rated their treatment satisfaction at the Day 73 visit on a 5-point scale ranging from -2 (very dissatisfied) to +2 (very satisfied)
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Subject Satisfaction With Treatment Assessment (SCTA) | 0.0 ± 1.31 | 0.9 ± 0.89 | 0.7 ± 0.93 | 0.1 ± 1.33 |
Subjects assessed their cellulite based on a 5-point scale from -1 (slightly worse), 0 (same), 1 (slightly improved), 2 (moderately improved), to 3 (much improved) on Day 73
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Subject Global Assessment Cellulite (SGA-C) | 0.9 ± 1.23 | 1.6 ± 0.85 | 1.5 ± 1.04 | 0.8 ± 0.96 |
Subjects's assessment of aesthetic improvement (C-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).
| units on a scale | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Subject Global Assessment of Aesthetic Improvement (C-GAIS) | 0.9 ± 1.14 | 1.6 ± 0.88 | 1.4 ± 1.03 | 0.7 ± 0.91 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 0.06 mg (Low Dose) | 0/43 (0%) | 1/43 (2.3%) | 28/43 (65.1%) |
| AA4500 0.48 mg (Mid-dose) | 0/43 (0%) | 0/43 (0%) | 31/43 (72.1%) |
| AA4500 0.84 mg (High Dose) | 0/40 (0%) | 0/40 (0%) | 31/40 (77.5%) |
| Placebo | 0/24 (0%) | 0/24 (0%) | 7/24 (29.2%) |
| Event | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Pharyngeal absessInfections and infestations | 1/43 | 0/43 | 0/40 | 0/24 |
| Event | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo |
|---|---|---|---|---|
| Injection site brusingGeneral disorders | 27/43 | 30/43 | 28/40 | 6/24 |
| Injection site painGeneral disorders | 11/43 | 18/43 | 21/40 | 2/24 |
| Injection site pruritusGeneral disorders | 0/43 | 5/43 | 7/40 | 0/24 |
| Injection site swellingGeneral disorders | 3/43 | 7/43 | 5/40 | 0/24 |
| Injection site discolorationGeneral disorders | 0/43 | 5/43 | 6/40 | 0/24 |
| Injection site indurationGeneral disorders | 0/43 | 0/43 | 3/40 | 0/24 |
| Injection site discomfortGeneral disorders | 0/43 | 0/43 | 2/40 | 0/24 |
| Injection site haemorrhageGeneral disorders | 0/43 | 0/43 | 2/40 | 0/24 |
| Injection site noduleGeneral disorders | 0/43 | 0/43 | 2/40 | 0/24 |
| Age, Continuous(years) | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 37.7 ± 5.78 | 36.8 ± 7.07 | 36.1 ± 5.62 | 37.3 ± 8.08 | 36.9 ± 6.50 |
| Age, Customized(Participants) | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo | Total |
|---|---|---|---|---|---|
| <25 | 2 | 3 | 2 | 1 | 8 |
| 25-34 | 6 | 11 | 12 | 6 | 35 |
| 35-44 | 33 | 23 | 25 | 13 | 94 |
| >=45 | 2 | 6 | 1 | 4 | 13 |
| Sex: Female, Male(Participants) | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo | Total |
|---|---|---|---|---|---|
| Female | 43 | 43 | 40 | 24 | 150 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 13 | 9 | 4 | 36 |
| Not Hispanic or Latino | 33 | 30 | 31 | 20 | 114 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo | Total |
|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 4 | 2 | 11 |
| White | 40 | 40 | 36 | 20 | 136 |
| Other | 1 | 0 | 0 | 1 | 2 |
| Region of Enrollment(participants) | AA4500 0.06 mg (Low Dose) | AA4500 0.48 mg (Mid-dose) | AA4500 0.84 mg (High Dose) | Placebo | Total |
|---|---|---|---|---|---|
| United States | 43 | 43 | 40 | 24 | 150 |
The record gives a start of Oct 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 2 years 11 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase